Need Help?
Copied to clipboard!

c-TRAK-CN : clonal evolution

In patients with moderate to high risk TNBC enrolled in the c-TRAK clinical trial, we exome sequenced 238 primary tumour-tissue samples from 149 patients, alongside tissue digital and multiplex-immunofluorescence pathology, to investigate factors associated with the development of Molecular Residual Disease (MRD) after curative intent therapy. We investigated tumour evolution from MRD detection to relapse in 291 ctDNA samples from 56 patients.

Cite

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD50000003204 unspecified 397